Page 73 - 2025中醫藥與天然藥物聯合學術研討會-中醫藥與天然藥物的挑戰Ｘ機遇與未來大會手冊

黃怡萱 教授 Yi-Shuian Huang, PhD

◼ Position/Affiliation/E-mail
Position/Affiliation:

Research Fellow & Deputy Director, Institute of Biomedical Sciences,
Academia Sinica
E-mail: yishuian@ibms.sinica.edu.tw

◼ Biography
Dr. Yi-Shuian Huang received a Ph.D. in Biochemistry and Molecular Biology from the
University of Texas Southwestern Medical Center and currently serves as Research Fellow and
Deputy Director at the Institute of Biomedical Sciences, Academia Sinica. Her research focuses

on the molecular basis of brain development and memory, particularly how experience-
dependent synaptic plasticity is regulated by RNA-binding proteins and cap methyltransferases
in the mammalian central nervous system.
A central theme of her work is understanding how localized translation of mRNAs at

synapses supplies plasticity-related proteins critical for long-term memory. Her group has
studied the cytoplasmic polyadenylation element-binding proteins (CPEBs) and uncovered
their roles in translation regulation, nucleocytoplasmic shuttling, and stress granule dynamics.
These efforts have resulted in 25 peer-reviewed publications and an invited Expert Review in

Molecular Psychiatry on “CPEB in Memory and Neurological Disorders.” Notably, her team
provided the first direct evidence that axonal translation, mediated by CPEB2, regulates
glutamatergic transmission, presynaptic plasticity, and memory formation.
Building on these findings, her current research investigates RNA epitranscriptomic

regulation in brain development and memory. Specifically, her group examines the roles of cap
methyltransferases CMTR1 and CMTR2. In parallel, two program projects are underway: one
explores how tau mRNA 3′-UTR length influences its localization, translation, and function in
synaptic plasticity; the other investigates CADASIL pathogenesis using mouse models.

Together, these studies aim to illuminate molecular pathways underlying neurodegenerative
and cerebrovascular disorders, paving the way for new therapeutic strategies.

51